Israel - hebreu - Ministry of Health

inovamed ltd - exemestane 25 mg - film coated tablets - exemestane - exemestane inovamed is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane inovamed is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemestane inovamed is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Israel - hebreu - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 0.5 mg; norethisterone acetate 0.1 mg - estradiol, combinations - estradiol, combinations - eviana is indicated for women who have a uterus for the: treatment of moderate to severe vasomotor symptoms associated with menopause. prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.

Israel - hebreu - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Israel - hebreu - Ministry of Health

organon pharma israel ltd., israel - tibolone - טבליה - tibolone 2.5 mg - tibolone - tibolone - complaints resulting from the natural or artificial menopause. prevention of osteoporosis in estrogen deficiency states. treatment of estrogen deficiency symptoms in postmenopausal women.

Israel - hebreu - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to,or have contraindication to or who are intolerant to other systemic therapies including ciclosporin,methotrexate and psoralen plus u.v (puva).

Israel - hebreu - Ministry of Health

j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen plus u.v (puva).

Israel - hebreu - Ministry of Health

amgen europe b.v. - apremilast - טבליות מצופות פילם - apremilast 10 mg - apremilast

Israel - hebreu - Ministry of Health

amgen europe b.v. - apremilast - טבליות מצופות פילם - apremilast 10 mg - apremilast

Israel - hebreu - Ministry of Health

amgen europe b.v. - apremilast - טבליות מצופות פילם - apremilast 10 mg - apremilast

Israel - hebreu - Ministry of Health

amgen europe b.v. - apremilast - טבליות מצופות פילם - apremilast 10 mg - apremilast